SML3043
XL188
≥98% (HPLC)
别名:
((R)-N-(3-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-4-oxo-3,4-dihydroquinazolin-7-yl)-3-(4-methylpiperazin-1-yl)propanamide, N-[3,4-Dihydro-3-[[4-hydroxy-1-[(3R)-1-oxo-3-phenylbutyl]-4-piperidinyl]methyl]-4-oxo-7-quinazolinyl]-4-methyl-1-piperazinepropanamide, XL-188
登录查看公司和协议定价
所有图片(1)
About This Item
质量水平
检测方案
≥98% (HPLC)
形式
powder
颜色
white to beige
溶解性
DMSO: 2 mg/mL, clear
储存温度
2-8°C
SMILES字符串
O=C1N(CC2(O)CCN(C(C[C@@H](C)C3=CC=CC=C3)=O)CC2)C=NC4=CC(NC(CCN5CCN(C)CC5)=O)=CC=C41
生化/生理作用
XL188 is a highly selective and potent (IC50 90 nM) non covalent inhibitor of USP7 that binds to the USP7 active site. XL188 facilitates degradation of HDM2, and increases the levels of p53 and p21 in MCF7 cells.
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Ilaria Lamberto et al.
Cell chemical biology, 24(12), 1490-1500 (2017-10-24)
Deubiquitinating enzymes (DUBs) have garnered significant attention as drug targets in the last 5-10 years. The excitement stems in large part from the powerful ability of DUB inhibitors to promote degradation of oncogenic proteins, especially proteins that are challenging to
Björn Stolte et al.
The Journal of experimental medicine, 215(8), 2137-2155 (2018-07-27)
Ewing sarcoma is a pediatric cancer driven by EWS-ETS transcription factor fusion oncoproteins in an otherwise stable genomic background. The majority of tumors express wild-type TP53, and thus, therapies targeting the p53 pathway would benefit most patients. To discover targets
Jonathan W Bushman et al.
Cell chemical biology, 28(1), 78-87 (2020-10-03)
Deubiquitinating enzymes (DUBs) catalyze the removal of ubiquitin, thereby reversing the activity of E3 ubiquitin ligases and are central to the control of protein abundance and function. Despite the growing interest in DUBs as therapeutic targets, cellular functions for DUBs
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门